Magnetic resonance imaging biomarkers of ischemic stroke: criteria for the validation of primary imaging biomarkers.

S. Pedraza, J. Puig, G. Blasco, J. Daunis-i-Estadella, I. Boada, A. Bardera, A. Prats, M. Castellanos, J. Serena
{"title":"Magnetic resonance imaging biomarkers of ischemic stroke: criteria for the validation of primary imaging biomarkers.","authors":"S. Pedraza, J. Puig, G. Blasco, J. Daunis-i-Estadella, I. Boada, A. Bardera, A. Prats, M. Castellanos, J. Serena","doi":"10.1358/dnp.2009.22.8.1413791","DOIUrl":null,"url":null,"abstract":"Ischemic stroke is associated with a high rate of disability and death. Establishing valid biomarkers could help accelerate the approval of promising new therapies for stroke. Whereas many serum biomarkers have been evaluated, possible imaging biomarkers of stroke lack validation. Magnetic resonance imaging (MRI) is a very sensitive technique to study acute stroke and MRI parameters have been established to assess the outcome of acute stroke. This review reassesses the criteria for the validation of MRI biomarkers of acute ischemic stroke (MRI-BAS). Seven criteria were used to review the validity of the main MRI-BAS: vascular status, lesion volume, reversibility on diffusion-weighted imaging, perfusion alteration, penumbra studied with diffusion-perfusion mismatch, clinical-diffusion mismatch, diffusion-angiography mismatch and hemorrhagic transformation. We analyzed the definitions of these biomarkers and the extent to which each fulfills the criteria for validation and found that few MRI-BAS have been fully validated. Further studies should help to improve the validation of current MRI-BAS and develop new biomarkers.","PeriodicalId":11325,"journal":{"name":"Drug news & perspectives","volume":"16 1","pages":"481-6"},"PeriodicalIF":0.0000,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug news & perspectives","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dnp.2009.22.8.1413791","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14

Abstract

Ischemic stroke is associated with a high rate of disability and death. Establishing valid biomarkers could help accelerate the approval of promising new therapies for stroke. Whereas many serum biomarkers have been evaluated, possible imaging biomarkers of stroke lack validation. Magnetic resonance imaging (MRI) is a very sensitive technique to study acute stroke and MRI parameters have been established to assess the outcome of acute stroke. This review reassesses the criteria for the validation of MRI biomarkers of acute ischemic stroke (MRI-BAS). Seven criteria were used to review the validity of the main MRI-BAS: vascular status, lesion volume, reversibility on diffusion-weighted imaging, perfusion alteration, penumbra studied with diffusion-perfusion mismatch, clinical-diffusion mismatch, diffusion-angiography mismatch and hemorrhagic transformation. We analyzed the definitions of these biomarkers and the extent to which each fulfills the criteria for validation and found that few MRI-BAS have been fully validated. Further studies should help to improve the validation of current MRI-BAS and develop new biomarkers.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
缺血性脑卒中的磁共振成像生物标志物:主要成像生物标志物的验证标准。
缺血性中风与高致残率和死亡率有关。建立有效的生物标志物可以帮助加快有希望的中风新疗法的批准。尽管许多血清生物标志物已被评估,但可能的脑卒中成像生物标志物缺乏验证。磁共振成像(MRI)是研究急性脑卒中的一项非常敏感的技术,已经建立了评估急性脑卒中预后的MRI参数。本综述重新评估了急性缺血性卒中MRI生物标志物(MRI- bas)的验证标准。采用7项标准评价主要MRI-BAS的有效性:血管状态、病变体积、弥散加权成像可逆性、灌注改变、伴有弥散-灌注不匹配的半暗区、临床-弥散不匹配、弥散-血管成像不匹配和出血转化。我们分析了这些生物标志物的定义以及每个生物标志物满足验证标准的程度,发现很少有MRI-BAS得到了充分的验证。进一步的研究应有助于提高现有MRI-BAS的有效性,并开发新的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drug news & perspectives
Drug news & perspectives 医学-药学
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊最新文献
Osteopontin. Trends in medicinal chemistry. Molecule of the Month. The significance of GlgE as a new target for tuberculosis. Inhibition of potassium currents as a pharmacologic target for investigation in chronic lymphocytic leukemia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1